Abstract
Bone remodelling is a strictly regulated dynamic process between bone resorption and bone formation. Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis (SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes the current knowledge of IL-17 signalling pathways. Typical IL-17–mediated bone destruction disorders are examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory loss of bone targeting IL-17.
Keywords: IL-17, IL-17 receptor, bone loss, osteoclastogensis, RANKL, osteoclasts.
Current Pharmaceutical Design
Title:Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases
Volume: 23 Issue: 41
Author(s): Chongshan Liao, Chengfei Zhang and Yanqi Yang*
Affiliation:
- Orthodontics, Faculty of Dentistry, The University of Hong Kong, Sai Ying Pun, Hong Kong SAR,China
Keywords: IL-17, IL-17 receptor, bone loss, osteoclastogensis, RANKL, osteoclasts.
Abstract: Bone remodelling is a strictly regulated dynamic process between bone resorption and bone formation. Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis (SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes the current knowledge of IL-17 signalling pathways. Typical IL-17–mediated bone destruction disorders are examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory loss of bone targeting IL-17.
Export Options
About this article
Cite this article as:
Liao Chongshan , Zhang Chengfei and Yang Yanqi *, Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases, Current Pharmaceutical Design 2017; 23 (41) . https://dx.doi.org/10.2174/1381612823666170519120040
DOI https://dx.doi.org/10.2174/1381612823666170519120040 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Susceptibility Risk Alleles of -238G/A, -308G/A and -1031T/C Promoter Polymorphisms of TNF-α Gene to Uterine Leiomyomas
Recent Advances in DNA & Gene Sequences (Discontinued) Periodontal Regenerative Materials and Their Applications: Mechanisms of Action
Recent Patents on Regenerative Medicine Investigation of Methylene Blue Release from Functional Polymeric Systems Using Dielectric Analysis
Current Drug Delivery Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Chemical Sensing Regulates Mastication/Swallowing
Current Pharmaceutical Design Mucoadhesive Polymers for Oral Transmucosal Drug Delivery: A Review
Current Pharmaceutical Design Bone Regeneration by Synthetic Octacalcium Phosphate and its Role in Biological Mineralization
Current Medicinal Chemistry Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Current Neuropharmacology Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Towards Personalized Regenerative Cell Therapy: Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells
Current Stem Cell Research & Therapy Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Medium-Term Culture of Primary Oral Squamous Cell Carcinoma in a Three- Dimensional Model: Effects on Cell Survival Following Topical 5-Fluororacile Delivery by Drug-Loaded Matrix Tablets
Current Pharmaceutical Design Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases
Current Medicinal Chemistry Editorial [ Immune-Mediated Mechanisms in Atheroclerosis:Prevention and Treatment of Clinical Manifestations Executive Editor: Emilio Jirillo ]
Current Pharmaceutical Design Editorial: [Hot Topic: Bio-Pharmaceutics and Materials in Oral Cavity]
Current Pharmaceutical Design Perichondrial Progenitor Cells in Cartilage Tissue Engineering and Regenerative Medicine
Current Tissue Engineering (Discontinued) Flavonoids: A Review of Its Commercial Application Potential as Anti- Infective Agents
Current Medicinal Chemistry - Anti-Infective Agents